Stabilized Human Cytomegalovirus GB Polypeptide Variants for Niche Applications

The inventive concept relates to engineered mutants of human cytomegalovirus glycoprotein B (gB) protein, adapted for specific, narrow markets or unique operational environments, such as high-security bioresearch facilities, disaster relief operations, extreme weather condition research, high-security biodefense applications, and high-altitude research stations.

The original patent disclosed engineered mutants of human cytomegalovirus glycoprotein B (gB) protein, but these mutants may not be suitable for use in specific, niche environments that require enhanced stability, sensitivity, or potency. The inventive concept addresses this limitation by adapting the engineered mutants for these unique operational environments.

The inventive concept comprises engineered mutants of human cytomegalovirus glycoprotein B (gB) protein, wherein the mutants comprise at least two amino acid mutations, including at least one engineered disulfide mutation. These mutants are designed to provide enhanced stability, sensitivity, or potency in specific, niche environments. For example, the mutants may be used in high-security bioresearch facilities, disaster relief operations, extreme weather condition research, high-security biodefense applications, and high-altitude research stations. The mutants may be administered as part of a vaccine composition, used in a kit for research, or incorporated into a device for detection.

The inventive concept is novel and non-obvious over the original patent because it adapts the engineered mutants for specific, niche environments, providing enhanced stability, sensitivity, or potency. The inventive concept's novelty lies in the specific combinations of mutations and environments, which are not anticipated by the original patent.

Alternative embodiments of the inventive concept may include different combinations of mutations, different environments, or different methods of administration. For example, the mutants may be used in other types of research stations, such as underwater or space-based research stations. The mutants may also be used in combination with other therapeutic agents or diagnostic tools.

The inventive concept has significant commercial potential in various industries, including biotechnology, pharmaceuticals, and research institutions. The adapted mutants may be used in a variety of applications, including vaccine development, diagnostic tools, and research reagents. The target market includes high-security bioresearch facilities, disaster relief organizations, extreme weather condition research institutions, high-security biodefense agencies, and high-altitude research stations.